Although vaccine delivery using the Oligomer scaffold elicited significantly higher antibody responses and IFNγ+CD4+ T cells, a limitation of this study is the lack of direct evidence demonstrating the effectiveness of these responses against viral or tumor challenges. The gene discussed is CD4; the disease is neoplasm.